We have entered a new era of clinical development.
In response to COVID-19, the industry brought clinical trials closer to patients – most of whom had to stay at home – at a scale never achieved before. Site access constraints and elevated concerns about patient safety sparked regulatory agencies to expand their guidance to include the use of virtual clinical trial tools.
Many sponsors and clinical research organizations embraced this opportunity to utilize innovative, flexible clinical trials models and approaches to ensure critical drug development continued through the pandemic and beyond.
Leverage a global network of Phase I clinical pharmacology units to build diversity in patient populations and access a range of geographic regions for early clinical development (ECD) programs.
Change the model of clinical research by integrating data, expertise, analytics and technology from study design through execution to power better decisions.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
